April 2025 FDA Recall Chlorpromazine Hydrochloride by Zydus Pharmaceuticals (usa) Inc (D-0361-2025 - CGMP deviations)

This Class II drug recall was voluntarily initiated by Zydus Pharmaceuticals (usa) Inc on April 3, 2025 for the product Chlorpromazine Hydrochloride. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently ongoing.

Recall Number: D-0361-2025

Reason for Recall
CGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit
Initiated
04-03-2025
Reported
04-16-2025
Quantity
3144 bottles, pack size: 100's Count

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Zydus Pharmaceuticals (USA) Inc
Nationwide within U.S - MS, AL, TN, VT, OH, ND, MN, WI, SC, AR, FL, IN, LA, NJ, AZ, TX, KY and PA
chlorproMAZINE Hydrochloride Tablets, USP 10 mg, Rx Only, 100 Tablets bottles, Manufactured by: Zydus Lifesciences Ltd., Baddi, India, Distributed by: Zydus Pharmaceuticals (USA) Inc., Pennington, NJ 08534, NDC 70710-1129-1

Batch or Lot Expiration Information

Lot# : Z400069, Exp.: 12/31/2025